
About
Matthew P. Smeltzer, PhD, MStat, is Professor of Epidemiology and Biostatistics and Helen and Jabie Hardin Endowed Professor of Public Health. He is a 2019 Fellow of the National Cancer Institute (NCI) Training Institute for Dissemination and Implementation Research in Cancer. Dr. Smeltzer's primary focus is clinical epidemiology with research interests including clinical outcomes, cancer staging, screening, disease surveillance, and implementation science in cancer and sickle cell disease. His work is currently funded by the National Cancer Institute (NCI), National Heart, Lung and Blood Institute (NHLBI), and the US Centers for Disease Control and Prevention (CDC). Dr. Smeltzer has more than 150 peer-reviewed publications, with additional research experience in childhood cancer, ovarian cancer, breast cancer, immunology, anesthesiology, and biomedical engineering. He enjoys teaching Epidemiologic Methods, Applied Biostatistics, and training doctoral students.
Dr. Smeltzer serves as Chair of the Methodology Committee and member of the Executive Committee for the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Group for development of the 10th edition AJCC/UICC staging system for lung cancer, thymic tumors, and mesothelioma. He is Principal Investigator of the Tennessee sickle cell disease surveillance program (SCDC) funded by the CDC. Dr. Smeltzer is the quantitative lead for the Mid-South Quality of Surgical Resection (MS-QSR) and the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta cohorts. He also serves on the steering committee for the St. Jude Sickle Cell Clinical Research and Intervention Program (SCCRIP) cohort. Prior to joining the ÌÇÐÄvlogÃÛÌÒ faculty, Dr. Smeltzer spent 11 years in the Department of Biostatistics at St. Jude Children's Research Hospital and was Accredited as a Professional Statistician by the American Statistical Association.
Selected Publications
- Smeltzer, M. P., Liao, W., Goss, J., Qureshi, T., Johnson, S., Harris, A., Dortch, K., Fehnel, C., Ely, S., Ray, M. A., & Osarogiagbon, R. (2025). Reducing smoking requirements for lung screening to address health disparities in a community cohort. JAMA Network Open, 8(6), e2517149.
- Smeltzer, M. P., King, J. C., Connolly, C., Brunson, K., Chau, M., Chen, S., Kerpel-Fronius, A., Lantuejoul, S., Mohan, A., Plaxco, A., Roy, U. B., Santos, R., Soo, R., Woodard, G., Wynes, M. W., Yatabe, Y., Young, A., & Kelly, K. (2025). The 2024 International Association for the Study of Lung Cancer (IASLC) global survey on biomarker testing. Journal of Thoracic Oncology, 20(12), 1801–1813.
- Pimenta, K., Edwards, J., Ray, M., Naser, A. M., Price, C., Idassi, O., Strong, K., Were, W., Piel, F. B., Hankins, J. S., & Smeltzer, M. P. (2026). Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis. British Journal of Haematology.
- Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N., Osarogiagbon, R., Mino-Kenudson, M., Yatabe, Y., Higgins, K., Desai, A., Reckamp, K. L., Lin, J., Liu, S., Hegi-Johnson, F., Seetharamu, N., Harpole, D., Mazotti, J., Edelman, M., & IASLC Communications Committee. (2025). 50 years of progress in non-small cell lung cancer: A new fellow’s guide in the clinic. Journal of Thoracic Oncology.
- Smeltzer, M. P., Akinbobola, O. A., Ray, M. A., Fehnel, C., Saulsberry, A., Dortch, K. R., Pimenta, K., Matthews, A. T., & Osarogiagbon, R. U. (2024). Prevalence of epidermal growth factor receptor and programmed death-ligand 1 testing in a population-based lung cancer surgical resection cohort from 2018–2022. Cancer Epidemiology, Biomarkers & Prevention, 33(8), 1098–1106.
- Plaxco, A. P., Hankins, J. S., Davis, R. L., Dudley, J., Young, A. J., Mukhopadyay, A., Carroll, Y. M., Aguinaga, M. D. P., Takemoto, C. M., Nolan, V. G., Ray, M. A., Wiese, A., Amosun, T. A., Cooper, W. O., & Smeltzer, M. P. (2023). Descriptive epidemiology of sickle cell disease in Tennessee: Population-based estimates from 2008 to 2019. Frontiers in Hematology, 2, Article 1277548.
- Smeltzer, M. P., & Ray, M. A. (2022). Statistical considerations for outcomes in clinical research: A review of common data types and methodology. Experimental Biology and Medicine, 247(9), 734–742.
- Osarogiagbon, R. U., Liao, W., Faris, N. R., Meadows-Taylor, M., Fehnel, C., Lane, J., Williams, S. C., Patel, A. A., Akinbobola, O. A., Pacheco, A., Epperson, A., Luttrell, J., McCoy, D., McHugh, L., Signore, R., Bishop, A. M., Tonkin, K., Optican, R., Wright, J., Robbins, T., Ray, M. A., & Smeltzer, M. P. (2022). Lung cancer in persons participating in screening, lung nodule program and neither: A prospective observational study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta cohort. Journal of Clinical Oncology, 40(19), 2094–2105.
- Smeltzer, M. P., Faris, N. R., Ray, M. A., & Osarogiagbon, R. U. (2018). Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent. JAMA Oncology, 4(1), 1–8.
- Mathias, J. G., Nolan, V. G., Klesges, L. M., Badawy, S. M., Cooper, W. O., Hankins, J. S., & Smeltzer, M. P. (2021). Hydroxyurea utilization following transitions of care among young adults with sickle cell disease enrolled in Tennessee Medicaid. JAMA Network Open, 4(10), e2128971.
